Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression in multiple disease areas by selective inhibition of transcription factors in the cell nucleus. The lead compound CB-103 has advanced to Phase 2 successfully treating patients with multi-drug resistant cancers.

Further, Cellestia is advancing a rich R&D pipeline of novel transcription factor inhibitors, in oncology, auto-immune and inflammatory disorders, having achieved animal in-vivo proof of concept for several new targets. Cellestia was founded in 2014 as a spin-off from EPFL, Lausanne, Switzerland and is headquartered in Basel, Switzerland.

pioneering.svg

WE ARE RELENTLESS IN OUR PURSUIT OF

Pioneering science

We aspire to  address unmet medical needs by developing innovative first-in-class therapies which can make previously undruggable targets druggable.

patients.svg

WE ARE RESOLUTE IN OUR

Dedication to patients

There is no compromise to our dedication to the patients we serve. We put their needs first and are resolute in our search for groundbreaking novel therapies.

health.svg

WE EXTEND AND IMPROVE

Quality of life

We are developing safe and therapeutic solutions to extend and improve the quality of life for patients who currently have no other treatment options.

cure.svg

WE ASPIRE TO

Cure cancer

We aspire to reach true breakthroughs in cancer treatments and therapies that will ultimately lead to a cure for previously incurable cancers.

futur.svg

WE DO WHATEVER IT TAKEs TO

Shape the future

We hold each other responsible and accountable to the vision and goals we share as we carve our own path forward.

all_in.svg

We are all in

We understand what is at stake for patients and their families and as a result we are willing to put our reputations, time with our loved ones and our own resources on the line. We are all in.

History

Based on more than 10 years of academic research led by the company’s CSO, Rajwinder Lehal, Cellestia was founded in 2014 as spin-off from the prestigious Swiss Institute for Experimental Cancer Research (ISREC), based at the École Polytechnique Fédérale de Lausanne (EPFL), a world-renowned centre of excellence in Switzerland. Originally incubated at ISREC, today Cellestia has established its independent research facilities at Biopôle in Lausanne and in close proximity to Ludwig Institute for Cancer Research, Swiss Cancer Center Léman, Le Centre hospitalier universitaire vaudois (CHUV), and University of Lausanne and EPFL. In addition, multiple international research collaborations have been established.

2012

First patent application filed

2015

Michael Bauer joins
and the HQ move to Basel

2017

 IND filed
Mode of action identified

2019

Safety and Efficacy Data
Series B completed

                                                  2021

Start of Phase II Oncology
Global Expansion of Development Program CB-103

adn-v3

2008

Transcription Factors Inhibitors Research starts with Raj Lehal’s doctoral thesis

2014

Foundation of Cellestia in Lausanne

2016

CB-103 development begins
First series financing and team expansion

2018

Start of Clinical Development in Oncology
Series A completed

2020

Clinical Proof of Concept CB-103

History

2008

Transcription Factors Inhibitors Research starts with Raj Lehal’s doctoral thesis

2012

First patent application filed

2014

Foundation of Cellestia in Lausanne

2015

Michael Bauer joins
and the HQ move to Basel

2016

• CB-103 development begins
• First series financing and team expansion

2017

• IND filed
• Mode of action identified

2018

• Start of Clinical Development in Oncology
• Series A completed

2019

• Safety and Efficacy Data
• Series B completed

2020

Clinical Proof of Concept CB-103

2021

• Start of Phase II Oncology
• Global Expansion of Development Program CB-103

If my research can make a difference for even one single patient, I would consider this the reward of my lifetime.

Cellestia is the first company to control NOTCH-positive cancers safely and effectively in any cancer patient, closing a major gap in today’s cancer therapy.

Clinical & Research Collaboration

Cellestia has established a global clinical development and research collaboration with Europe, US and Asia.

Adenoid Cystic Carcinoma Research Foundation
University of Cincinnati
EPFL
IOR - Institute of Oncology Research
Universitats Kinderspital Zurich
MD Anderson Cancer Network
Swiss Institute of Bioinformatics
Universitatsklinikum Schleswig-Holstein
VHIO
The Christie NHS Foundation Trust
Harvrad Medical School
Penn - Univesity of Pennsylvania
LSU Health - New Orleans
Unil - Université de Lausanne
Brigham Health - Brigham and Women's Hospital